Holen Sie sich die Stockscreener-App
3.78
2.58%
-0.10
Schlusskurs vom Vortag:
$3.88
Offen:
$3.89
24-Stunden-Volumen:
3.74M
Relative Volume:
1.22
Marktkapitalisierung:
$744.84M
Einnahmen:
$71.80M
Nettoeinkommen (Verlust:
$-183.59M
KGV:
-3.5853
EPS:
-1.0543
Netto-Cashflow:
$-186.52M
1W Leistung:
+0.00%
1M Leistung:
-22.54%
6M Leistung:
-48.08%
1J Leistung:
-46.15%
1-Tages-Spanne:
$3.77
$3.96
1-Wochen-Bereich:
$3.555
$4.07
52-Wochen-Spanne:
$3.555
$21.73
Wave Life Sciences Ltd Stock (WVE) Company Profile
Firmenname
Wave Life Sciences Ltd
Sektor
Branche
Telefon
617-949-2900
Adresse
7 STRAITS VIEW, SINGAPORE
Compare WVE vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
WVE
Wave Life Sciences Ltd
|
3.78 | 744.84M | 71.80M | -183.59M | -186.52M | -1.0543 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-29 | Fortgesetzt | Truist | Buy |
| 2026-02-05 | Eingeleitet | BofA Securities | Buy |
| 2025-12-12 | Bestätigt | Wedbush | Outperform |
| 2025-12-09 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-08-04 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-07-28 | Eingeleitet | Oppenheimer | Outperform |
| 2025-07-16 | Eingeleitet | Citigroup | Buy |
| 2025-06-11 | Fortgesetzt | Raymond James | Outperform |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Eingeleitet | Wedbush | Outperform |
| 2025-02-25 | Eingeleitet | Jefferies | Buy |
| 2024-10-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-09-27 | Fortgesetzt | JP Morgan | Overweight |
| 2024-09-19 | Eingeleitet | B. Riley Securities | Buy |
| 2024-09-09 | Eingeleitet | JP Morgan | Overweight |
| 2024-05-15 | Eingeleitet | Wells Fargo | Overweight |
| 2023-12-19 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | Eingeleitet | Raymond James | Outperform |
| 2023-05-24 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-31 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-11-01 | Eingeleitet | Guggenheim | Buy |
| 2019-07-15 | Eingeleitet | Cowen | Market Perform |
| 2019-04-17 | Bestätigt | H.C. Wainwright | Buy |
| 2018-08-07 | Eingeleitet | Stifel | Buy |
| 2018-07-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-19 | Bestätigt | Mizuho | Buy |
| 2017-02-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-11-10 | Fortgesetzt | Leerink Partners | Outperform |
| 2015-12-07 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-12-07 | Eingeleitet | Jefferies | Buy |
| 2015-12-07 | Eingeleitet | Leerink Partners | Outperform |
| 2015-12-07 | Eingeleitet | Sun Trust Rbsn Humphrey | Buy |
Alle ansehen
Wave Life Sciences Ltd Aktie (WVE) Neueste Nachrichten
WVE Initiates Coverage On Wave Life Sciences -- Buy Rating Annou - GuruFocus
Wave Life Sciences (WVE) Shares Rise After FDA Confirms Registra - GuruFocus
Wave Life, FDA agree on plans for AATD therapy (WVE:NASDAQ) - Seeking Alpha
Wave Life Sciences reaches FDA alignment on WVE-006 trial design - Investing.com
FDA supports a one-year data check for possible faster approval of Wave's treatment. - Stock Titan
Ladenburg Thalmann Initiates Wave Life Sciences at Buy With $10 Price Target - marketscreener.com
How Is GSK (LSE:GSK) Stock Reacting This Week To Its Wave Life Sciences Liver Candidate? - Kalkine Media
Wave Life Sciences, Inc. (WVE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Wave Life Sciences stock gets a USD 12.0 million GSK boost - AD HOC NEWS
Wave Life Sciences Announces GSK Advances Hepatology Candidate from SpiNA siRNA Collaboration - Quiver Quantitative
GSK selected a liver candidate for development, triggering $12 million for Wave. - Stock Titan
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation - TradingView
WVE Stock Edges Up After Positive Early Data For Rare Disease Drug - Stocktwits
Wave Life Sciences Initiates Phase 2a Trial of Obesity Drug WVE-007 in Combination With Tirzepatide - marketscreener.com
This Autoliv Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
Wave Life Sciences starts Phase 2a obesity trial for WVE-007 - Investing.com India
Wave Life Sciences starts Phase 2a obesity trial for WVE-007 By Investing.com - Investing.com South Africa
Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity - Stock Titan
JPMorgan resumes Wave Life Sciences stock rating at Neutral By Investing.com - Investing.com Australia
JPMorgan resumes Wave Life Sciences stock rating at Neutral - Investing.com
Wave Life Sciences stock hits a 52-week low at USD 4.20 - AD HOC NEWS
Wave Life Sciences Names Monika Vnuk Chief Business Officer - citybiz
Wave Life Sciences appoints Monika Vnuk as chief business officer By Investing.com - Investing.com Australia
Wave Life Sciences appoints Monika Vnuk as chief business officer - Investing.com
Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer - The Manila Times
Wave Life Sciences Appoints Monika Vnuk as Chief Business Officer - Quiver Quantitative
Wave Life Sciences at Cantor conference: RNA editing gains traction By Investing.com - Investing.com Nigeria
Wave Life Sciences at Cantor conference: RNA editing gains traction - investing.com
WAVE Life Sciences (WVE) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Wave Life Sciences Ltd. (WVE) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Wave Life Sciences stock holds steady ahead of Cantor healthcare conference appearance - ad-hoc-news.de
Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference - GlobeNewswire
Wells Fargo Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $14 - Moomoo
WVE Q2 2026 Earnings: EPS Misses Estimates as Clinical-Stage RNA Pipeline Investment ContinuesEarnings Trend Analysis - dars.gov.et
Wave Life Sciences stock trades quietly as investors focus on recent clinical progress - AD HOC NEWS
Wave Life Sciences Ltd. (WVE) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
WAVE Life Sciences (NASDAQ:WVE) Downgraded by Zacks Research to "Hold" - MarketBeat
Wave Life Sciences (WVE) Files To Deregister Its Ordinary Shares - simplywall.st
What Went Wrong For WVE? The Obesity Drug Trial Data That Spooked Investors - Stocktwits
Wave Life Sciences targets fat loss without sacrificing muscle - Longevity.Technology
Insiders Sold Wave Life Sciences Prematurely At US$13.64 With Stock Trading Higher - Moomoo
Wave Life Sciences (WVE) Pulls Back 5.2% to $5.13 as Support Holds at $4.87Thematic ETF Flow - vinanet.vn
Wave Life Sciences Ltd. SEC Filing (Aug 17, 2026) - Stock Titan
Precision Trading with Wave Life Sciences Ltd. (WVE) Risk Zones - Stock Traders Daily
Wave Life Sciences, Inc.: Top Mutual Funds Holders | WVE | US94352A1043 - marketscreener.com
Wave Life Sciences, Inc.: Target Price Consensus and Analysts Recommendations | WVE | US94352A1043 - marketscreener.com
Wave Life Sciences, Inc.: Performance & Quotes, WVE Stock Price on Nasdaq Exchange - marketscreener.com
Wave Life Sciences, Inc.: Fundamental Analysis and Financial Ratings | WVE | US94352A1043 - marketscreener.com
Wave Life Sciences, Inc.: Financial Data Forecasts Estimates and Expectations | WVE | US94352A1043 - marketscreener.com
Wave Life Sciences, Inc. Stock (WVE)Quote Nasdaq - marketscreener.com
Q1 2025 WAVE Life Sciences Ltd Earnings Call Transcript - GuruFocus
Finanzdaten der Wave Life Sciences Ltd-Aktie (WVE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Wave Life Sciences Ltd-Aktie (WVE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Wagner Heidi L | Director |
Aug 11 '26 |
Sale |
6.01 |
7,000 |
42,070 |
44,930 |
| Rawcliffe Adrian | Director |
Aug 12 '26 |
Sale |
5.29 |
12,700 |
67,183 |
0 |
| TAKANASHI KEN | Director |
Aug 11 '26 |
Sale |
6.01 |
3,864 |
23,223 |
20,079 |
| Tan Aik Na | Director |
Aug 11 '26 |
Sale |
6.01 |
432 |
2,596 |
24,968 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):